The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment ...
Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
Bristol-Myers Squibb remains a "Buy" despite recent price ... risks from patent expirations but has promising new drugs like Cobenfy to offset potential revenue declines. Recent quarterly results ...
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed recently. As the Federal Reserve exits the year ...